Related Experiment Video
Updated: Aug 19, 2026

Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
Published on: March 10, 2015
Disease-associated prion protein elicits immunoglobulin M responses in vivo
Mourad Tayebi1, Perry Enever, Zahid Sattar
1MRC Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London, UK.
Abstract:
Prion diseases such as Creutzfeldt-Jakob disease are believed to result from the misfolding of a widely expressed normal cellular prion protein, PrPc. The resulting disease-associated isoforms, PrP(Sc), have much higher beta-sheet content, are insoluble in detergents, and acquire relative resistance to proteases. Although known to be highly aggregated and to form amyloid fibrils, the molecular architecture of PrP9Sc) is poorly understood. To date, it has been impossible to elicit antibodies to native PrP(Sc) that are capable of recognizing PrP(Sc) without denaturation, even in Pm-P(o/o) mice that are intolerant of it. Here we demonstrate that antibodies for native PrPc and PrP(Sc) can be produced by immunization of Pm-P(o/o) mice with partially purified PrPc and PrP(Sc) adsorbed to immunomagnetic particles using high-affinity anti-PrP monoclonal antibodies (mAbs). Interestingly, the polyclonal response to PrP(Sc) was predominantly of the immunoglobulin M (IgM) isotype, unlike the immunoglobulin G (IgG) responses elicited by PrP(c) or by recombinant PrP adsorbed or not to immunomagnetic particles, presumably reflecting the polymeric structure of disease-associated prion protein. Although heat-denatured PrP(Sc) elicited more diverse antibodies with the revelation of C-terminal epitopes, remarkably, these were also predominantly IgM suggesting that the increasing immunogenicity, acquisition of protease sensitivity, and reduction in infectivity induced by heat are not associated with dissociation of the PrP molecules in the diseased-associated protein. Adsorbing native proteins to immunomagnetic particles may have general applicability for raising polyclonal or monoclonal antibodies to any native protein, without attempting laborious purification steps that might affect protein conformation.
Insights
Researchers developed a new method to create antibodies for native prion proteins, PrPc and PrP(Sc), using immunomagnetic particles. This technique overcomes challenges in studying misfolded prion structures and may aid in developing diagnostics for prion diseases.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Prion diseases stem from misfolded cellular prion protein (PrPc) into disease-associated isoforms (PrP(Sc)).
- PrP(Sc) exhibits higher beta-sheet content, insolubility, and protease resistance, with poorly understood molecular architecture.
- Generating antibodies to native PrP(Sc) without denaturation has been a significant challenge.
Purpose of the Study:
- To develop a method for producing antibodies against native PrPc and PrP(Sc).
- To investigate the antibody response to native and denatured PrP(Sc).
- To explore the potential of immunomagnetic particle-based immunization for antibody generation.
Main Methods:
- Immunization of PrP-ablated mice (PrP-P(o/o)) with partially purified PrPc and PrP(Sc) adsorbed to immunomagnetic particles.
- Utilizing high-affinity anti-PrP monoclonal antibodies for adsorption.
- Analyzing the isotype (IgM vs. IgG) and epitope recognition of elicited polyclonal antibodies.
Main Results:
- Successfully produced polyclonal antibodies recognizing native PrPc and PrP(Sc).
- The polyclonal response to PrP(Sc) was predominantly IgM, unlike the IgG response to PrPc.
- Heat-denatured PrP(Sc) also elicited predominantly IgM antibodies, suggesting structural integrity despite denaturation-induced changes.
Conclusions:
- Adsorption to immunomagnetic particles is effective for generating antibodies to native prion proteins.
- The predominant IgM response to PrP(Sc) may reflect its polymeric structure.
- This method offers broad applicability for antibody production against native proteins without extensive purification.

